Study finds fourth dose of Moderna or Pfizer vaccine provides “substantial” boost in COVID-19 immunity
A fourth dose is already authorized in the U.S. for people 50 and older.
A fourth dose is already authorized in the U.S. for people 50 and older.
New data shows COVID-19 hospitalizations and deaths are on track to rise for the first time in months, and the FDA is encouraging Americans to get either the Moderna or Pfizer vaccines over the Johnson & Johnson shot.
Some big news for parents. The COVID-19 vaccine could be available for children under five-years-old by summer.
Kids ages 5-11 may soon be eligible for a COVID-19 booster shot. Pfizer and BioNTech plan to submit for emergency use authorization, after the companies say results from a study reveal a third vaccine dose in that age group shows “high immune response.”
Pfizer wants to expand its COVID-19 booster shots to healthy 5- to 11-year-olds. Pfizer said Thursday new data shows its kid-sized booster could help healthy elementary-aged children rev up virus-fighting antibodies.
Health care providers hoping to get new guidance on coronavirus vaccines from the FDA will have to keep waiting. Wednesday’s meeting ended with no solid answers regarding the future of booster shots and regular vaccines.
U.S. regulators are allowing people 50 and older to get another booster dose of the Pfizer or Moderna COVID-19 vaccine.
Pfizer is petitioning to the FDA for a second COVID-19 booster shot for older Americans. This comes as we see potential warning signs of a new rise in coronavirus infections.
Officials say while a third shot helps protect against hospitalization and death, it’s not that good at protecting against infections.
A COVID-19 antiviral treatment for children could soon be on the way.